Drug Trial Radar · NCT01467362
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
251
Actual
Start
Nov 2011
Primary completion
May 2012
Study completion May 2012
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local, immunological, genetic and environmental factors. Important symptoms of atopic dermatitis are dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is associated with skin barrier dysfunction that facilitates an easier allergen penetration into the skin with an increased irritation and subsequent cutaneous inflammation. A lack of important stratum corneum intercellular lipids and an inadequate ratio between compounds enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy usually twice daily improves dryness and subsequently pruritus during the treatment of atopic dermatitis and especially improves the barrier function. Emollients make part of basic therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology and Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier alteration, measured by skin hydration, is a key element for evaluation of emollient treatment efficacy. The primary objective of this study is to demonstrate the efficacy of the tested product (V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient formula during 28 days.
Conditions
- Atopic Dermatitis
Interventions
V0034CR01BDrug
Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
Vehicle creamDrug
Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
desonide 0.1% creamDrug
cream, once a day (in the evening) during flares
Foaming gelOther
for the washing and cleaning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Xerosis score: mean evolution over the different time-points of double-blind periodTime frame: During 28 days (Day 1, Day 7, Day 14, Day 21 and Day 28)
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Estonia
Tallinn, Estonia
Estonia
Tartu, Estonia
France
Bordeaux, France
France
Martigues, France
France
Nantes, France
France
Nice, France
France
Poitiers, France
Lithuania
Vilnius, Lithuania
Poland
Bialystok, Poland
Poland
Inowrocław, Poland
Poland
Lodz, Poland
Poland
Oleśnica, Poland
Poland
Płock, Poland
Poland
Poznan, Poland
Poland
Strzelce Opolskie, Poland
Poland
Warsaw, Poland
Poland
Żyrardów, Poland
Romania
Brasov, Romania
Romania
Bucharest, Romania
Romania
Constanța, Romania
Romania
Craiova, Romania
Romania
Iași, Romania
Romania
Ploieşti, Romania
Romania
Sibiu, Romania
Romania
Târgu Mureş, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.